Duke to start trial of promising COVID treatment
If effective, the antibody trial could advance COVID care until a vaccine is developed by providing an antibody treatment.
Posted — UpdatedOn Sunday, Duke announced that the Duke Human Vaccine Institute (DHVI) was given approval for a clinical trial that, if effective, could advance COVID care until a vaccine can be developed.
The approval means the DHVI can launch Phase 1 of the clinical trial for one of the most promising antibody treatments for COVID-19.
The DHVI is also developing a pan-coronavirus vaccine to combat future iterations of COVID-19 or similar viruses, as well as if saliva could be used as an accurate indicator for COVID-19, according to Duke Today.
This video released by Duke Health Development provides a deeper look into the trials and potential for the antibody treatment.
Related Topics
• Credits
Copyright 2024 by Capitol Broadcasting Company. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.